Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Kangsheng Gu"'
Autor:
Jiujie Cui, Shukui Qin, Yuhong Zhou, Shuang Zhang, Xiaofeng Sun, Mingjun Zhang, Jiuwei Cui, Weijia Fang, Kangsheng Gu, Zhihua Li, Jufeng Wang, Xiaobing Chen, Jun Yao, Jun Zhou, Gang Wang, Yuxian Bai, Juxiang Xiao, Wensheng Qiu, Bangmao Wang, Tao Xia, Chunyue Wang, Li Kong, Jiajun Yin, Tao Zhang, Xionghu Shen, Deliang Fu, Chuntao Gao, Huan Wang, Quanren Wang, Liwei Wang
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-9 (2024)
Abstract Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-control
Externí odkaz:
https://doaj.org/article/7a7dcbcd35414399b2d9715ea43ed0fe
Autor:
Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li
Publikováno v:
Cancer Communications, Vol 44, Iss 8, Pp 910-914 (2024)
Externí odkaz:
https://doaj.org/article/53acf5bc101a47cdb61c89a6accc0936
Publikováno v:
Thoracic Cancer, Vol 15, Iss 11, Pp 919-928 (2024)
Abstract Background Splicing factor B subunit 4 (SF3B4) has been confirmed to participate in the progression of many cancers and is considered to be a potential target for non‐small cell lung cancer (NSCLC). Thus, the role and molecular mechanism o
Externí odkaz:
https://doaj.org/article/ddad363dfe3240c6a25b5a77cc930017
Autor:
Qianling Wang, Yiyin Zhang, Wenxi Ding, Cheng Feng, Yuyan Wang, Xiaoli Wei, Ziting Qu, Hui Wang, Xiaoying Liu, Hua Wang, Kangsheng Gu
Publikováno v:
Genes and Diseases, Vol 11, Iss 2, Pp 575-578 (2024)
Externí odkaz:
https://doaj.org/article/af4ccb2ab51641f89684dd8ac963aa8c
Autor:
Min Li, Lingling Liao, Wei Huang, Hui Feng, Wanqing Wang, Nana Huang, Zhiyan Zhao, Yu Shi, Jinglu Ye, Kangsheng Gu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 2
Externí odkaz:
https://doaj.org/article/f636f6a042a14e9baf122765f32688bc
Autor:
Zhihao Lu, Li Kong, Buhai Wang, Junye Wang, Lianke Liu, Yongqian Shu, Lei Yang, Guogui Sun, Guochun Cao, Yinghua Ji, Tongjian Cui, Hu Liu, Wensheng Qiu, Na Li, Gaofeng Li, Hui Luo, Xinfang Hou, Yanqiao Zhang, Wenbin Yue, Liying Xue, Zheng Liu, Yueyin Pan, Shegan Gao, Xiuwen Wang, Zhanyu Pan, Shuqun Zhang, Gen Lin, Yanru Xie, Kangsheng Gu, Tiejun Ren, Weidong Li, Tao Li, Shoufeng Wang, Wei He, Yun Fan, Jun Liang, Bing Xia, Li Zhao, Shuxuan Wang, Lin Shen
Publikováno v:
EClinicalMedicine, Vol 72, Iss , Pp 102623- (2024)
Summary: Background: In ORIENT-15 study, sintilimab plus chemotherapy demonstrated significant improvement on overall survival (OS) versus placebo plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC). Here,
Externí odkaz:
https://doaj.org/article/3439ece3dd7b46968792b2d1c86fbbe8
Autor:
Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang
Publikováno v:
Cancer Medicine, Vol 13, Iss 10, Pp n/a-n/a (2024)
Abstract Objective To explore the efficacy of serplulimab plus chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with liver metastases. Methods A post hoc exploratory analysis of ASTRUM‐007 study was performed, focusing on the asso
Externí odkaz:
https://doaj.org/article/853c821061684aecbd227cf8265e2157
Autor:
Lin Yang, Wen Zhang, Nanfeng Fan, Peiguo Cao, Ying Cheng, Lingjun Zhu, Suxia Luo, Hong Zong, Yuxian Bai, Jianfeng Zhou, Yanhong Deng, Yi Ba, Tianshu Liu, Mayinuer Aili, Xianli Yin, Kangsheng Gu, Guanghai Dai, Jieer Ying, Jianhua Shi, Yajie Gao, Wei Li, Guohua Yu, Liangzhi Xie, Wenlin Gai, Yan Wang, Peng Meng, Yuankai Shi
Publikováno v:
EBioMedicine, Vol 100, Iss , Pp 104966- (2024)
Summary: Background: Limited therapeutic options are available for metastatic colorectal cancer (mCRC) patients after failure of first- and second-line therapies, representing an unmet medical need for novel therapies. Methods: This is an open-label,
Externí odkaz:
https://doaj.org/article/51a30c01a2774b8782efcb9593d768c2
Autor:
Yuankai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Changlu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for AL
Externí odkaz:
https://doaj.org/article/fa1f8545777d42219ff4b4af29402825
Autor:
Fengying Wu, Tao Jiang, Gongyan Chen, Yunchao Huang, Jianying Zhou, Lizhu Lin, Jifeng Feng, Zhehai Wang, Yongqian Shu, Jianhua Shi, Yi Hu, Qiming Wang, Ying Cheng, Jianhua Chen, Xiaoyan Lin, Yongsheng Wang, Jianan Huang, Jiuwei Cui, Lejie Cao, Yunpeng Liu, Yiping Zhang, Yueyin Pan, Jun Zhao, LiPing Wang, Jianhua Chang, Qun Chen, Xiubao Ren, Wei Zhang, Yun Fan, Zhiyong He, Jian Fang, Kangsheng Gu, Xiaorong Dong, Tao Zhang, Wei Shi, Jianjun Zou, Xuejuan Bai, Shengxiang Ren, Caicun Zhou, the CameL Study Group
Publikováno v:
Cancer Communications, Vol 42, Iss 12, Pp 1331-1346 (2022)
Abstract Background Although programmed cell death 1 (PD‐1) blockade plus chemotherapy can significantly prolong the progression‐free survival (PFS) and overall survival (OS) in first‐line settings in patients with driver‐negative advanced no
Externí odkaz:
https://doaj.org/article/29c625b2073e4405bfa35cd6c6aed633